Viracta Therapeutics Inc To Discuss Nana-val For The Treatment Of Advanced Epstein-Barr Virus-Positive Solid Tumors Call Transcript
Good morning, and welcome to the Viracta Therapeutics KOL Webinar. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Viracta website following the conclusion of the event. I'd now like to turn the call over to your host, Dr. Ivor Royston, President and Chief Executive Officer of Viracta Therapeutics. Please go ahead, Ivor.
Okay. Thank you very much, (inaudible). It is my pleasure to be speaking with you at our KOL event today. We are pleased to partner with LifeSci Advisors for this event and what is an exciting time for Viracta.
Next slide. Before we begin, I'd like to remind you that certain statements in this presentation may be forward looking, and I invite you to visit our website to review our SEC filings and to read about the risks associated with such statements. For those of you who may be new to Viracta, the company lies at the intersection of virology and oncology, targeting virus-associated malignancies. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
